120 related articles for article (PubMed ID: 27885740)
21. RNAi technology targeting the
Parker Kerrigan BC; Ledbetter D; Kronowitz M; Phillips L; Gumin J; Hossain A; Yang J; Mendt M; Singh S; Cogdell D; Ene C; Shpall E; Lang FF
Neurooncol Adv; 2020; 2(1):vdaa132. PubMed ID: 33241214
[TBL] [Abstract][Full Text] [Related]
22. Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.
Pal SK; Grivas P; Gupta S; Dizman N; Zengin Z; Valderrama BP; Rodriguez-Vida A; Roghmann F; Sevillano Fernandez E; Matin SF; Loriot Y; Sridhar SS; Sonpavde G; Fleming MT; Lerner SP; Bellmunt J; Master V; Tripathi A; Davis K; van Veenhuyzen D; Weng R; Daneshmand S
Eur Urol; 2024 Apr; ():. PubMed ID: 38580518
[No Abstract] [Full Text] [Related]
23. Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
Ebiike H; Taka N; Matsushita M; Ohmori M; Takami K; Hyohdoh I; Kohchi M; Hayase T; Nishii H; Morikami K; Nakanishi Y; Akiyama N; Shindoh H; Ishii N; Isobe T; Matsuoka H
J Med Chem; 2016 Dec; 59(23):10586-10600. PubMed ID: 27933954
[TBL] [Abstract][Full Text] [Related]
24. An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors.
Cheng W; Wang M; Tian X; Zhang X
Eur J Med Chem; 2017 Jan; 126():476-490. PubMed ID: 27914362
[TBL] [Abstract][Full Text] [Related]
25. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
[TBL] [Abstract][Full Text] [Related]
26. Therapeutics Targeting FGF Signaling Network in Human Diseases.
Katoh M
Trends Pharmacol Sci; 2016 Dec; 37(12):1081-1096. PubMed ID: 27992319
[TBL] [Abstract][Full Text] [Related]
27. Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
Chandrani P; Prabhash K; Prasad R; Sethunath V; Ranjan M; Iyer P; Aich J; Dhamne H; Iyer DN; Upadhyay P; Mohanty B; Chandna P; Kumar R; Joshi A; Noronha V; Patil V; Ramaswamy A; Karpe A; Thorat R; Chaudhari P; Ingle A; Choughule A; Dutt A
Ann Oncol; 2017 Mar; 28(3):597-603. PubMed ID: 27998968
[TBL] [Abstract][Full Text] [Related]
28. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
Leong SR; Sukumaran S; Hristopoulos M; Totpal K; Stainton S; Lu E; Wong A; Tam L; Newman R; Vuillemenot BR; Ellerman D; Gu C; Mathieu M; Dennis MS; Nguyen A; Zheng B; Zhang C; Lee G; Chu YW; Prell RA; Lin K; Laing ST; Polson AG
Blood; 2017 Feb; 129(5):609-618. PubMed ID: 27908880
[TBL] [Abstract][Full Text] [Related]
29. Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer.
Inokuchi M; Murase H; Otsuki S; Kawano T; Kojima K
World J Surg Oncol; 2017 Jan; 15(1):2. PubMed ID: 28056982
[TBL] [Abstract][Full Text] [Related]
30. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
31. In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
Guffanti F; Chilà R; Bello E; Zucchetti M; Zangarini M; Ceriani L; Ferrari M; Lupi M; Jacquet-Bescond A; Burbridge MF; Pierrat MJ; Damia G
Neoplasia; 2017 Jan; 19(1):35-42. PubMed ID: 27988457
[TBL] [Abstract][Full Text] [Related]
32. A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors.
Del Piccolo N; Sarabipour S; Hristova K
J Biol Chem; 2017 Jan; 292(4):1288-1301. PubMed ID: 27927983
[TBL] [Abstract][Full Text] [Related]
33. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.
Datta J; Damodaran S; Parks H; Ocrainiciuc C; Miya J; Yu L; Gardner EP; Samorodnitsky E; Wing MR; Bhatt D; Hays J; Reeser JW; Roychowdhury S
Mol Cancer Ther; 2017 Apr; 16(4):614-624. PubMed ID: 28255027
[TBL] [Abstract][Full Text] [Related]
34. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with
Pal SK; Rosenberg JE; Hoffman-Censits JH; Berger R; Quinn DI; Galsky MD; Wolf J; Dittrich C; Keam B; Delord JP; Schellens JHM; Gravis G; Medioni J; Maroto P; Sriuranpong V; Charoentum C; Burris HA; Grünwald V; Petrylak D; Vaishampayan U; Gez E; De Giorgi U; Lee JL; Voortman J; Gupta S; Sharma S; Mortazavi A; Vaughn DJ; Isaacs R; Parker K; Chen X; Yu K; Porter D; Graus Porta D; Bajorin DF
Cancer Discov; 2018 Jul; 8(7):812-821. PubMed ID: 29848605
[TBL] [Abstract][Full Text] [Related]
36. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Perera TPS; Jovcheva E; Mevellec L; Vialard J; De Lange D; Verhulst T; Paulussen C; Van De Ven K; King P; Freyne E; Rees DC; Squires M; Saxty G; Page M; Murray CW; Gilissen R; Ward G; Thompson NT; Newell DR; Cheng N; Xie L; Yang J; Platero SJ; Karkera JD; Moy C; Angibaud P; Laquerre S; Lorenzi MV
Mol Cancer Ther; 2017 Jun; 16(6):1010-1020. PubMed ID: 28341788
[TBL] [Abstract][Full Text] [Related]
37. AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts.
Nakamura K; Inami M; Morio H; Okuma K; Ito M; Noto T; Shirakami S; Hirose J; Morokata T
Eur J Pharmacol; 2017 Feb; 796():69-75. PubMed ID: 27993641
[TBL] [Abstract][Full Text] [Related]
38. Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.
Nelson KN; Peiris MN; Meyer AN; Siari A; Donoghue DJ
Trends Mol Med; 2017 Jan; 23(1):59-79. PubMed ID: 27988109
[TBL] [Abstract][Full Text] [Related]
39. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with
Hahn NM; Bivalacqua TJ; Ross AE; Netto GJ; Baras A; Park JC; Chapman C; Masterson TA; Koch MO; Bihrle R; Foster RS; Gardner TA; Cheng L; Jones DR; McElyea K; Sandusky GE; Breen T; Liu Z; Albany C; Moore ML; Loman RL; Reed A; Turner SA; De Abreu FB; Gallagher T; Tsongalis GJ; Plimack ER; Greenberg RE; Geynisman DM
Clin Cancer Res; 2017 Jun; 23(12):3003-3011. PubMed ID: 27932416
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]